Suppliers and packagers for TRAVATAN Z
✉ Email this page to a colleague
TRAVATAN Z
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Sandoz | TRAVATAN Z | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021994 | NDA AUTHORIZED GENERIC | Sandoz Inc | 0781-6185-56 | 1 BOTTLE in 1 CARTON (0781-6185-56) / 2.5 mL in 1 BOTTLE | 2019-12-18 |
| Sandoz | TRAVATAN Z | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021994 | NDA AUTHORIZED GENERIC | Sandoz Inc | 0781-6185-75 | 1 BOTTLE in 1 CARTON (0781-6185-75) / 5 mL in 1 BOTTLE | 2019-12-18 |
| Sandoz | TRAVATAN Z | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021994 | NDA AUTHORIZED GENERIC | Bryant Ranch Prepack | 63629-8839-1 | 1 BOTTLE in 1 CARTON (63629-8839-1) / 5 mL in 1 BOTTLE | 2019-12-18 |
| Sandoz | TRAVATAN Z | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021994 | NDA AUTHORIZED GENERIC | Bryant Ranch Prepack | 63629-8840-1 | 1 BOTTLE in 1 CARTON (63629-8840-1) / 2.5 mL in 1 BOTTLE | 2019-12-18 |
| Sandoz | TRAVATAN Z | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021994 | NDA | Sandoz Inc | 66758-095-56 | 1 BOTTLE in 1 CARTON (66758-095-56) / 2.5 mL in 1 BOTTLE | 2006-10-20 |
| Sandoz | TRAVATAN Z | travoprost | SOLUTION/DROPS;OPHTHALMIC | 021994 | NDA | Sandoz Inc | 66758-095-75 | 1 BOTTLE in 1 CARTON (66758-095-75) / 5 mL in 1 BOTTLE | 2006-10-20 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: TRAVATAN Z
Introduction
Travatan Z (generic: travoprost ophthalmic solution) represents a widely prescribed medication for glaucoma and ocular hypertension, marketed under the brand name Travatan Z. As a prostaglandin analog, it reduces intraocular pressure (IOP), thereby preventing optic nerve damage associated with glaucoma. The global demand for this drug has surged owing to rising prevalence of glaucoma and eye health awareness, prompting the identification and analysis of key suppliers involved across the manufacturing, distribution, and supply chain networks. This article offers an in-depth overview of the primary suppliers for Travatan Z, examining their roles, market positioning, and strategic significance for stakeholders.
Manufacturers of Travatan Z
AbbVie (Abbott Laboratories)
AbbVie, a leading biopharmaceutical company, acquired the rights for Travatan Z from Alcon, a Novartis affiliate, in 2019. As the original manufacturer, AbbVie maintains production, regulatory approvals, and supply chain networks for Travatan Z globally. Its extensive manufacturing facilities in the United States and Europe ensure consistent quality and supply continuity. AbbVie's global market presence accelerates distribution, especially in North America, Europe, and parts of Asia.
Alcon (Novartis)
Prior to the transfer of rights in 2019, Alcon was a main producer of Travatan Z, leveraging its specialized ophthalmic manufacturing expertise. Post-transaction, Alcon shifted focus to other ophthalmic products, but historically, it played a significant role in the supply chain. Its manufacturing excellence set industry standards for ophthalmic solutions, including Travatan Z.
Generic Manufacturers
Once the patent exclusivity period for Travatan Z expired, multiple generic pharmaceutical companies entered the market, significantly increasing supply options. These manufacturers include:
- Fresenius Kabi: A German multinational specializing in injectable, infusion, and ophthalmic medicines, providing generic travoprost formulations to regions with less brand penetration.
- Sandoz (Novartis): Engages in producing generic ophthalmic agents, including travoprost formulations for markets with high demand for cost-effective alternatives.
- Mylan (now part of Viatris): Offers generic travoprost solutions, expanding access globally, particularly in emerging markets.
The entry of generics has improved drug accessibility, reduced prices, and contributed to increased supply reliability for Travatan Z.
Distribution and Supply Chain Entities
Wholesalers and Distributors
Major pharmaceutical distributors facilitate the critical link between manufacturers and healthcare providers:
- McKesson Corporation: A leading US-based pharmaceutical distributor, McKesson supplies Travatan Z to hospitals, clinics, and pharmacies across North America.
- AmerisourceBergen: Provides extensive pharmaceutical distribution services, ensuring timely delivery and inventory management for eye care products, including Travatan Z.
- Alliance Healthcare (NHS Supply Chain in the UK): Distributes ophthalmic medications, including Travatan Z, across the UK’s healthcare system.
Regional and Local Suppliers
In regions where regulatory approvals differ or local manufacturing is essential, regional suppliers serve as key players:
- Indian generic manufacturers (e.g., Sun Pharma, Lupin): Supply cost-effective Travatan Z equivalents in India and Southeast Asia, supporting local ophthalmology markets.
- Chinese pharmaceutical companies: Increasingly involved in the production of ophthalmic solutions, although regulatory oversight can vary.
Online Pharmacies and E-Distributors
The rise of digital health channels has introduced new suppliers of prescription ophthalmic medications; platforms such as Dr. Reddy’s or international online pharmacies source and distribute Travatan Z globally, expanding access but also requiring stringent regulatory compliance.
Supply Chain Dynamics and Challenges
Regulatory Approvals
Suppliers must secure approvals from authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regional regulators. Variations in approval status influence manufacturer market entry and thus supply availability.
Patent and Patent Expiry Impact
As patent protections for Travatan Z expire, generic manufacturers enter markets, transforming supply landscapes. This transition often prompts shifts in supplier dominance, pricing pressures, and increased competition.
Manufacturing Capacity and Quality Control
High-quality manufacturing adhering to Good Manufacturing Practices (GMP) remains a priority. Disruptions in production—e.g., due to raw material shortages, regulatory issues, or geopolitical factors—can impact global supply volumes and stability.
Supply Chain Risks
Global events, such as pandemics, geopolitical conflicts, or natural disasters, pose risks to the continuous supply of Travatan Z. Strategic stockpiling, diversified supplier bases, and regional manufacturing facilities mitigate these risks.
Market and Strategic Trends
Growth of Generic Competition
The proliferation of generic travoprost options has heightened supply volumes, lowered costs, and broadened access. Suppliers focus on manufacturing efficiency and regulatory compliance to capture market share.
Regional Manufacturing Expansion
Emerging markets are witnessing increased investments in local manufacturing, driven by demand and regulatory incentives, thus enhancing supply resilience.
Supply Chain Digitalization
Advanced tracking, AI-driven demand forecasting, and supply chain integration improve responsiveness and robustness for Travatan Z suppliers.
Conclusion
The supply landscape for Travatan Z encompasses a blend of original manufacturers, generic producers, and a global network of distributors. While AbbVie's established manufacturing infrastructure remains the core pillar, the expansion of generics post-patent expiry has diversified supply sources, reducing costs and increasing access. Strategic suppliers now emphasize regulatory compliance, supply chain resilience, and regional manufacturing capacity to meet growing demand, especially amid geopolitical and logistical challenges.
Key Takeaways
- Dominant Manufacturers: AbbVie remains the principal supplier, with generics from Fresenius Kabi, Sandoz, and Viatris supplementing the supply chain.
- Market Dynamics: Patent expirations have expanded supplier base and enhanced affordability, though supply chain risks persist.
- Distribution Network: Major global wholesalers and regional distributors are crucial in ensuring consistent availability, especially in emerging markets.
- Supply Chain Resilience: Geopolitical factors, regulatory hurdles, and manufacturing capacity influence supply chain stability; diversification remains essential.
- Growth Opportunities: Regional manufacturing expansion and digital supply chain innovations are strategic priorities for suppliers seeking competitive advantage.
FAQs
1. Who are the main current manufacturers of Travatan Z?
AbbVie is the primary manufacturer, with generic options produced by Fresenius Kabi, Sandoz, and Viatris, especially post-patent expiry.
2. How has patent expiry impacted the supply of Travatan Z?
Patent expiry facilitated the entry of generic competitors, increasing supply volume, reducing prices, and expanding global access.
3. What regions have the most diverse suppliers for Travatan Z?
North America, Europe, and select Asian markets feature the most diverse supplier base, including both original and generic manufacturers.
4. What are the major supply chain risks for Travatan Z?
Regulatory delays, raw material shortages, geopolitical tensions, and logistical disruptions pose significant risks.
5. How are digital technologies influencing the supply of Travatan Z?
Supply chain digitalization enhances forecasting, inventory management, and traceability, improving resilience and responsiveness.
Sources
More… ↓
